# Clinical trial results:
# Phase III, non-randomised, open-label study to evaluate the safety and immunogenicity of a prime-boost schedule of the H1N1 candidate vaccine adjuvanted with AS03B administered to subjects aged 3 to 17 years.

## Summary

| | |
|---|---|
| EudraCT number | 2009-015011-41 |
| Trial protocol | DE |
| Global end of trial date | 22 November 2010 |

**Results information**

| | |
|---|---|
| Result version number | v2 (current) |
| This version publication date | 06 March 2021 |
| First version publication date | 31 May 2015 |
| Version creation reason | • Correction of full data set<br>Minor corrections in safety section. |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | 113638 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00972517 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMEA-000725-PIP01-09 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 22 November 2010 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 22 November 2010 |
| Global end of trial reached? | Yes |
| Global end of trial date | 22 November 2010 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the humoral immune response after two primary administrations of the candidate H1N1 pandemic vaccine that meets or exceeds the EMEA (CHMP) guidance targets for pandemic vaccine seroconversion rate (SCR), seroprotection rate (SPR) and geometric mean fold rise (GMFR) at 21 days after the second dose of H1N1 vaccine in children aged 3 to 17 years.
To evaluate the superiority in terms of vaccine virus homologous haemagglutination inhibition (HI) antibody response of a single dose of the H1N1 candidate vaccine administered as a 6-month booster after 2-dose primary vaccination compared to the response after the first dose of primary vaccination.

Protection of trial subjects:

The subjects were observed closely for at least 30 minutes, with appropriate medical treatment readily available in case of anaphylaxis following the administration of vaccines.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 29 September 2009 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Germany: 245 |
| Worldwide total number of subjects | 245 |
| EEA total number of subjects | 245 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 123 |
| Adolescents (12-17 years) | 122 |
| Adults (18-64 years) | 0 |

| | |
|---|---|
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

One subject was enrolled but not vaccinated and therefore, was not included in the number of subjects under "started".

### Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

### Period 1

| | |
|---|---|
| Period 1 title | At Day 21 (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | No |
| **Arm title** | Flu BS1_3-5 Years Group |

Arm description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| | |
|---|---|
| **Arm title** | Flu BS1_6-9 Years Group |

Arm description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm

| **Arm title** | Flu BS1_10-17 Years Group |
|---|---|

Arm description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| **Arm title** | Flu BS2_3-5 Years Group |
|---|---|

Arm description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| **Arm title** | Flu BS2_6-9 Years Group |
|---|---|

Arm description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |

| | |
|---|---|
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| | |
|---|---|
| **Arm title** | Flu BS2_10-17 Years Group |

Arm description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| | |
|---|---|
| **Arm title** | Flu pooled_3-5 Years Group |

Arm description:

Pooled data of subjects aged 3 to 5 years from the Flu BS1 and Flu BS2 Groups

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| | |
|---|---|
| **Arm title** | Flu pooled_6-9 Years Group |

Arm description:

Pooled data of subjects aged 6 to 9 years from the Flu BS1 and Flu BS2 Groups

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| | |
|---|---|
| **Arm title** | Flu pooled_10-17 Years Group |

Arm description:

Pooled data of subjects aged 10 to 17 years from the Flu BS1 and Flu BS2 Groups

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | Pandemrix |
| Investigational medicinal product code | GSK2340272A |
| Other name | GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03 |
| Pharmaceutical forms | Emulsion for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Subjects received 2 doses of the Flu vaccine at Day 0 and 21, administered in the deltoid region of the non-dominant arm.

| **Number of subjects in period 1** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group |
|---|---|---|---|
| Started | 31 | 31 | 60 |
| Completed | 31 | 30 | 60 |
| Not completed | 0 | 1 | 0 |
| Consent withdrawn by subject | - | 1 | - |
| Adverse event, non-fatal | - | - | - |

| **Number of subjects in period 1** | Flu BS2_3-5 Years Group | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group |
|---|---|---|---|
| Started | 30 | 34 | 58 |
| Completed | 27 | 33 | 58 |
| Not completed | 3 | 1 | 0 |
| Consent withdrawn by subject | 2 | 1 | - |
| Adverse event, non-fatal | 1 | - | - |

| **Number of subjects in period 1** | Flu pooled_3-5 Years Group | Flu pooled_6-9 Years Group | Flu pooled_10-17 Years Group |
|---|---|---|---|
| Started | 61 | 65 | 118 |
| Completed | 58 | 63 | 118 |
| Not completed | 3 | 2 | 0 |
| Consent withdrawn by subject | 2 | 2 | - |
| Adverse event, non-fatal | 1 | - | - |

## Baseline characteristics

| Reporting groups[1] | |
|---|---|
| Reporting group title | At Day 21 |
| Reporting group description: - | |

Notes:

[1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.
Justification: Out of the 245 subjects enrolled in this trial, 1 subject did not receive vaccination even though the subject number had been allocated; hence he/she was excluded from the study start.

| Reporting group values | At Day 21 | Total | |
|---|---|---|---|
| Number of subjects | 244 | 244 | |
| Age categorical<br>Units: Subjects | | | |
| In utero | | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | | 0 | |
| Newborns (0-27 days) | | 0 | |
| Infants and toddlers (28 days-23 months) | | 0 | |
| Children (2-11 years) | | 0 | |
| Adolescents (12-17 years) | | 0 | |
| Adults (18-64 years) | | 0 | |
| From 65-84 years | | 0 | |
| 85 years and over | | 0 | |
| Age continuous<br>Units: years | | | |
| geometric mean | 9.2 | | |
| standard deviation | ± 4.15 | - | |
| Gender categorical<br>Units: Subjects | | | |
| Female | 116 | 116 | |
| Male | 128 | 128 | |

## End points

### End points reporting groups

| Reporting group title | Flu BS1_3-5 Years Group |
|---|---|

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| Reporting group title | Flu BS1_6-9 Years Group |
|---|---|

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| Reporting group title | Flu BS1_10-17 Years Group |
|---|---|

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| Reporting group title | Flu BS2_3-5 Years Group |
|---|---|

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| Reporting group title | Flu BS2_6-9 Years Group |
|---|---|

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| Reporting group title | Flu BS2_10-17 Years Group |
|---|---|

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| Reporting group title | Flu pooled_3-5 Years Group |
|---|---|

Reporting group description:

Pooled data of subjects aged 3 to 5 years from the Flu BS1 and Flu BS2 Groups

| Reporting group title | Flu pooled_6-9 Years Group |
|---|---|

Reporting group description:

Pooled data of subjects aged 6 to 9 years from the Flu BS1 and Flu BS2 Groups

| Reporting group title | Flu pooled_10-17 Years Group |
|---|---|

Reporting group description:

Pooled data of subjects aged 10 to 17 years from the Flu BS1 and Flu BS2 Groups

## Primary: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain

| End point title | Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain[1][2] |
|---|---|

End point description:

Antibody titers were expressed as Geometric mean titers (GMTs).

| End point type | Primary |
|---|---|

End point timeframe:

At Day 0, Day 21 and Day 42

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 28 | 30 | 54 | 25[3] |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 | 5.7 (4.5 to 7.2) | 5.2 (4.8 to 5.8) | 9.9 (7 to 14.1) | 0 (0 to 0) |
| H1N1, Day 21 | 192.6 (145.6 to 254.8) | 190.3 (147 to 246.3) | 479.3 (361.8 to 634.9) | 0 (0 to 0) |
| H1N1, Day 42 | 1361.7 (1107 to 1674.9) | 970.1 (765.8 to 1228.8) | 1069.4 (892.6 to 1281.3) | 1161.7 (905.2 to 1490.9) |

Notes:

[3] - This outcome measure was assessed only at Day 42 for the Flu BS2_3-5 Years Group.

| End point values | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 30[4] | 57[5] | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 | 0 (0 to 0) | 0 (0 to 0) | | |
| H1N1, Day 21 | 0 (0 to 0) | 0 (0 to 0) | | |
| H1N1, Day 42 | 915.7 (759.1 to 1104.6) | 979.6 (845.3 to 1135.2) | | |

Notes:

[4] - This outcome measure was assessed only at Day 42 for the Flu BS2_6-9 Years Group.

[5] - This outcome measure was assessed only at Day 42 for the Flu BS2_10-17 Years Group.

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

| End point title | Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain[6][7] |
|---|---|

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years.

| End point type | Primary |
|---|---|

End point timeframe:

At Day 42

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 28 | 30 | 54 | |
| Units: Subjects | | | | |
| H1N1 | 28 | 30 | 53 | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

| End point title | Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain[8][9] |
|---|---|

End point description:

A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (>) 70% in children aged 3 to 17 years.

| End point type | Primary |
|---|---|

End point timeframe:

At Day 42

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 28 | 30 | 54 | |
| Units: Subjects | | | | |
| H1N1 | 28 | 30 | 54 | |

### Statistical analyses

No statistical analyses for this end point

## Primary: HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain

| End point title | HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain[10][11] |
|---|---|

End point description:

GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The CHMP criterion was fulfilled if the point estimate for GMFR was greater than (>) 2.5 in children aged 3 to 17 years

| End point type | Primary |
|---|---|

End point timeframe:

At Day 42

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This outcome was descriptive; hence no statistical analyses were required.

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 28 | 30 | 54 | |
| Units: Fold increase | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 237.68 (175.28 to 322.29) | 185.25 (142.09 to 241.52) | 107.74 (76.64 to 151.45) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain

| End point title | Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain[12] |
|---|---|

End point description:

Antibody titers were expressed as geometric mean titers (GMTs)

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 6

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 27 | 28 | 53 | 23 |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 140.8 (118.2 to 167.6) | 154.2 (126.5 to 187.9) | 254.6 (199 to 325.7) | 129.4 (94.6 to 176.9) |

| End point values | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 27 | 47 | | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 148.2 (119 to 184.4) | 243.6 (185.9 to 319.3) | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain

| End point title | Humoral immune response in terms of Haemagglutination Inhibition (HI) antibody titers against the Flu A/California/7/2009 (H1N1) vaccine strain[13] |
|---|---|

End point description:

Antibody titers were expressed as geometric mean titers (GMTs)

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 12

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu BS2_3-5 Years Group | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 20 | 26 | 41 | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 48.5 (35.7 to 65.7) | 60.5 (49.2 to 74.3) | 132.8 (94.9 to 185.8) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

| End point title | Number of seroconverted subjects for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain[14] |
|---|---|

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years.

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 6

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 27 | 28 | 53 | |
| Units: Subjects | | | | |
| H1N1 | 27 | 28 | 50 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain

| End point title | Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain[15] |
|---|---|

End point description:

A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (>) 70% in children aged 3 to 17 years.

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 6

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 27 | 28 | 53 | 23 |
| Units: Subjects | | | | |
| H1N1 | 27 | 28 | 53 | 20 |

| End point values | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 27 | 47 | | |
| Units: Subjects | | | | |
| H1N1 | 27 | 47 | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects who were seroprotected for HI antibodies against

## the Flu A/California/7/2009 (H1N1) virus strain

| End point title | Number of subjects who were seroprotected for HI antibodies against the Flu A/California/7/2009 (H1N1) virus strain[16] |
|---|---|

End point description:

A seroprotected subject was defined as a vaccinated subject with a serum HI titre greater than or equal to (≥) 1:40, that usually is accepted as indicating protection. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the post-vaccination time point estimate for SPR the point estimate for SPR was greater than (>) 70% in children aged 3 to 17 years.

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 12

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS2_3-5 Years Group | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 20 | 26 | 41 | |
| Units: Subjects | | | | |
| H1N1 | 17 | 22 | 37 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain

| End point title | HI antibody geometric mean fold rise (GMFR) against the Flu A/California/7/2009 (H1N1) virus strain[17] |
|---|---|

End point description:

GMFR, also called seroconversion factor (SCF), was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The CHMP criterion was fulfilled if the point estimate for GMFR was greater than (>) 2.5 in children aged 3 to 17 years

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 6

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 27 | 28 | 53 | |
| Units: Fold increase | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 27.44 (22.42 to 33.57) | 29.35 (23.53 to 36.61) | 25.32 (18.6 to 34.47) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain

| End point title | Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain[18] |
|---|---|

End point description:

Antibody titers were expressed as Geometric mean titers (GMTs). This analysis was conducted on a subset of one third of the subjects who were randomly selected.

| End point type | Secondary |
|---|---|

End point timeframe:

At Day 0, Day 21, Day 42 and Month 6

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 16 | 15 | 14 | 12[19] |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 | 4.9 (3.9 to 6.1) | 7.1 (3.9 to 12.7) | 8 (3 to 21.3) | 0 (0 to 0) |
| H1N1, Day 21 | 27.7 (13 to 58.8) | 65.9 (24.6 to 176.4) | 109.4 (34.5 to 346.7) | 0 (0 to 0) |
| H1N1, Day 42 | 433.2 (295.2 to 635.6) | 473.7 (301.5 to 744.1) | 438.4 (191.3 to 1004.8) | 533.4 (298.4 to 953.7) |
| H1N1, Month 6 | 158.9 (110.4 to 228.8) | 203.3 (133.7 to 309.3) | 232.1 (81.8 to 658.4) | 156.6 (89.8 to 273.3) |

Notes:

[19] - This outcome measure was assessed only at Day 42 and Month 6 for the Flu BS2 Group.

| End point values | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 13 | 15[20] | | |

| Units: Titer | | | | |
|---|---|---|---|---|
| geometric mean (confidence interval 95%) | | | | |
| H1N1, Day 0 | 0 (0 to 0) | 0 (0 to 0) | | |
| H1N1, Day 21 | 0 (0 to 0) | 0 (0 to 0) | | |
| H1N1, Day 42 | 260.1 (141.9 to 476.6) | 199.5 (112.7 to 353.2) | | |
| H1N1, Month 6 | 166 (88.7 to 310.6) | 150.9 (62.7 to 363.1) | | |

Notes:

[20] - This outcome measure was assessed only at Day 42 and Month 6 for the Flu BS2 Group.

### Statistical analyses

No statistical analyses for this end point

## Secondary: Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain

| End point title | Humoral immune response in terms of neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) vaccine strain[21] |
|---|---|

End point description:

Antibody titers were expressed as Geometric mean titers (GMTs). This analysis was conducted on a subset of one third of the subjects who were randomly selected.

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 12

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu BS2_3-5 Years Group | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 12 | 12 | |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| H1N1 | 152.3 (88.8 to 261) | 129.9 (71.2 to 236.8) | 138.3 (71.6 to 267.2) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain

| End point title | Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain[22] |
|---|---|

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years. This analysis was conducted on a subset of one third of the subjects who were randomly selected.

| End point type | Secondary |
|---|---|

End point timeframe:

At Day 21 and Day 42

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 16 | 15 | 14 | |
| Units: Subjects | | | | |
| H1N1, Day 21 | 8 | 10 | 9 | |
| H1N1, Day 42 | 15 | 15 | 14 | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain

| End point title | Number of seroconverted subjects for neutralising antibodies against the Flu A/Netherlands/602/2009 (H1N1) virus strain[23] |
|---|---|

End point description:

A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titre less than (<) 1:10 and a post-vaccination titre greater than or equal to (≥) 1:40 or a pre-vaccination titre ≥ 1:10 and at least a 4-fold increase in post-vaccination titre. The Committee for Medicinal Products for Human Use (CHMP) criterion was fulfilled if the point estimate for SCR was greater than (>) 40% in children aged 3 to 17 years. This analysis was conducted on a subset of one third of the subjects who were randomly selected.

| End point type | Secondary |
|---|---|

End point timeframe:

At Month 6

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 16 | 15 | 13 | |
| Units: Subjects | | | | |
| H1N1 | 16 | 14 | 12 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting Any and Grade 3 solicited local symptoms

| End point title | Number of subjects reporting Any and Grade 3 solicited local symptoms[24] |
|---|---|

End point description:

Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as significant pain at rest that prevented normal everyday activities as assessed by inability to attend/do work or school or cried when limb was moved/spontaneously painful. Grade 3 redness and swelling was greater than 50 millimeters (mm) i.e. > 50mm.

| End point type | Secondary |
|---|---|

End point timeframe:

During the 7-day (Days 0-6) post-vaccination period

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu pooled_3-5 Years Group | Flu pooled_6-9 Years Group | Flu pooled_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 60 | 65 | 118 | |
| Units: Subjects | | | | |
| Any Pain | 40 | 49 | 96 | |
| Grade 3 Pain | 4 | 9 | 11 | |
| Any Redness | 28 | 28 | 46 | |
| Grade 3 Redness | 4 | 2 | 4 | |
| Any Swelling | 22 | 22 | 46 | |
| Grade 3 Swelling | 2 | 3 | 10 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting Any, Grade 3 and Related solicited general symptoms

| End point title | Number of subjects reporting Any, Grade 3 and Related solicited general symptoms[25] |
|---|---|

End point description:

Solicited general symptoms assessed were arthralgia, diarrhoea, drowsiness, fatigue, gastro-intestinal symptoms, headache, irritability, loss of appetite, myalgia, shivering, sweating and fever [axillary temperature above 37.5 degrees Celsius (°C)]. Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = axillary
temperature above 39.0°C

| End point type | Secondary |
|---|---|

End point timeframe:

During the 7-day (Days 0-6) post-vaccination period

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu pooled_3-5 Years Group | Flu pooled_6-9 Years Group | Flu pooled_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 60 | 65 | 118 | |
| Units: Subjects | | | | |
| Any Arthralgia | 0 | 14 | 25 | |
| Grade 3 Arthralgia | 0 | 1 | 3 | |
| Related Arthralgia | 0 | 14 | 23 | |
| Any Diarrhoea | 9 | 0 | 0 | |
| Grade 3 Diarrhoea | 2 | 0 | 0 | |
| Related Diarrhoea | 5 | 0 | 0 | |
| Any Drowsiness | 20 | 0 | 0 | |
| Grade 3 Drowsiness | 3 | 0 | 0 | |
| Related Drowsiness | 18 | 0 | 0 | |
| Any Fatigue | 0 | 24 | 53 | |
| Grade 3 Fatigue | 0 | 4 | 6 | |
| Related Fatigue | 0 | 23 | 50 | |
| Any Gastro-intestinal symptoms | 0 | 13 | 30 | |
| Garde 3 Gastro-intestinal symptoms | 0 | 1 | 5 | |
| Related Gastro-intestinal symptoms | 0 | 10 | 23 | |
| Any Headache | 0 | 19 | 61 | |
| Grade 3 Headache | 0 | 4 | 10 | |
| Related Headache | 0 | 19 | 56 | |
| Any Irritability | 18 | 0 | 0 | |
| Grade 3 Irritability | 1 | 0 | 0 | |
| Related Irritability | 18 | 0 | 0 | |
| Any Loss of appetite | 18 | 0 | 0 | |
| Grade 3 Loss of appetite | 1 | 0 | 0 | |
| Related Loss of appetite | 17 | 0 | 0 | |
| Any Myalgia | 0 | 13 | 45 | |
| Grade 3 Myalgia | 0 | 1 | 3 | |
| Related Myalgia | 0 | 13 | 43 | |
| Any Shivering | 10 | 10 | 35 | |
| Grade 3 Shivering | 0 | 0 | 3 | |
| Related Shivering | 9 | 9 | 33 | |
| Any Sweating | 9 | 10 | 18 | |

| | | | | |
|---|---|---|---|---|
| Grade 3 Sweating | 0 | 0 | 1 | |
| Related Sweating | 8 | 9 | 15 | |
| Any Fever (≥37.5°C) | 27 | 13 | 30 | |
| Grade 3 Fever (>39°C) | 4 | 3 | 4 | |
| Related Fever | 23 | 11 | 23 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting any Medically Attended Adverse Events (MAEs)

| End point title | Number of subjects reporting any Medically Attended Adverse Events (MAEs)[26] |
|---|---|

End point description:

MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination.

| End point type | Secondary |
|---|---|

End point timeframe:

During the entire study period (Day 0 to Month 12)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 31 | 31 | 60 | 30 |
| Units: Subjects | | | | |
| Subjects with any MAE(s) | 22 | 19 | 36 | 24 |

| End point values | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 58 | | |
| Units: Subjects | | | | |
| Subjects with any MAE(s) | 16 | 34 | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting any Adverse Events of Specific Interest

## (AESI)/potential immune-mediated diseases (pIMDs)

| End point title | Number of subjects reporting any Adverse Events of Specific Interest (AESI)/potential immune-mediated diseases (pIMDs)[27] |
|---|---|

End point description:

Potential immune-mediated diseases (pIMDs) were defined as a subset of adverse events that included both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which might or might not have an autoimmune etiology. "Any pIMD" was defined as at least one pIMD experienced by the study subject.

| End point type | Secondary |
|---|---|

End point timeframe:

During the entire study period (Day 0 to Month 12)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| **End point values** | Flu pooled_3-5 Years Group | Flu pooled_6-9 Years Group | Flu pooled_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 61 | 65 | 118 | |
| Units: Subjects | | | | |
| Subjects with any AESI(s)/pIMD(s) | 0 | 0 | 0 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting any, grade 3 and related unsolicited adverse events (AEs).

| End point title | Number of subjects reporting any, grade 3 and related unsolicited adverse events (AEs).[28] |
|---|---|

End point description:

An unsolicited AE was defined as any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.

| End point type | Secondary |
|---|---|

End point timeframe:

Within the 84-day after the first vaccination or from 63-day follow-up period after the second vaccination

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu pooled_3-5 Years Group | Flu pooled_6-9 Years Group | Flu pooled_10-17 Years Group | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 61 | 65 | 118 | |
| Units: Subjects | | | | |
| Any AE(s) | 42 | 25 | 53 | |
| Grade 3 AE(s) | 3 | 1 | 5 | |
| Related AE(s) | 9 | 2 | 4 | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects reporting any and related serious adverse events (SAEs)

| End point title | Number of subjects reporting any and related serious adverse events (SAEs)[29] |
|---|---|

End point description:

A serious adverse event was any untoward medical occurrence that: resulted in death, was life threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.

| End point type | Secondary |
|---|---|

End point timeframe:

During the entire study period (Day 0 to Month 12)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 31 | 31 | 60 | 30 |
| Units: Subjects | | | | |
| Any SAE(s) | 1 | 1 | 1 | 1 |
| Related SAE(s) | 0 | 0 | 0 | 0 |

| End point values | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 34 | 58 | | |
| Units: Subjects | | | | |
| Any SAE(s) | 0 | 3 | | |
| Related SAE(s) | 0 | 0 | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with normal and abnormal haematological and biochemistry parameters with respect to Alanine aminotransferase (ALAT), Aspartate aminotransferase (ASAT), Total Bilirubin, Bilirubin Conjugated / Direct,Creatine and Blood urea nitrogen(BUN)

| End point title | Number of subjects with normal and abnormal haematological and biochemistry parameters with respect to Alanine aminotransferase (ALAT), Aspartate aminotransferase (ASAT), Total Bilirubin, Bilirubin Conjugated / Direct,Creatine and Blood urea nitrogen(BUN)[30] |
|---|---|

End point description:

Subjects were categorized by age and according to their results at pre-vaccination (Day 0), Day 21, Day 42 and Month 6 which were below, within and above the normal ranges or unknown

| End point type | Secondary |
|---|---|

End point timeframe:

At Day 0, Day 21, Day 42 and Month 6 (M6)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The results in this study were tabulated by age group and study period. Hence for each related endpoint, they are presented for only the respective groups in the baseline period, while the results for multiple endpoints account for all baseline groups.

| End point values | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group | Flu BS2_3-5 Years Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 31 | 31 | 60 | 26[31] |
| Units: Subjects | | | | |
| ALAT, Day 0 Unknown | 1 | 1 | 1 | 0 |
| ALAT, Day 0 Below | 0 | 0 | 0 | 0 |
| ALAT, Day 0 Within | 29 | 30 | 58 | 0 |
| ALAT, Day 0 Above | 0 | 0 | 1 | 0 |
| ALAT, Day 21 Unknown | 1 | 0 | 1 | 0 |
| ALAT, Day 21 Below | 0 | 0 | 0 | 0 |
| ALAT, Day 21 Within | 30 | 30 | 58 | 0 |
| ALAT, Day 21 Above | 0 | 0 | 0 | 0 |
| ALAT, Day 42 Unknown | 0 | 0 | 2 | 0 |
| ALAT, Day 42 Below | 0 | 0 | 0 | 0 |
| ALAT, Day 42 Within | 31 | 30 | 55 | 26 |
| ALAT, Day 42 Above | 0 | 0 | 1 | 0 |
| ALAT, M6 Unknown | 0 | 0 | 1 | 0 |
| ALAT, M6 Below | 0 | 0 | 0 | 0 |
| ALAT, M6 Within | 30 | 29 | 56 | 24 |
| ALAT, M6 Above | 0 | 0 | 1 | 0 |
| ASAT, Day 0 Unknown | 1 | 1 | 1 | 0 |

| | | | | |
|---|---|---|---|---|
| ASAT, Day 0 Below | 0 | 0 | 0 | 0 |
| ASAT, Day 0 Within | 26 | 29 | 58 | 0 |
| ASAT, Day 0 Above | 3 | 1 | 1 | 0 |
| ASAT, Day 21 Unknown | 1 | 0 | 1 | 0 |
| ASAT, Day 21 Below | 0 | 0 | 0 | 0 |
| ASAT, Day 21 Within | 30 | 29 | 58 | 0 |
| ASAT, Day 21 Above | 0 | 1 | 0 | 0 |
| ASAT, Day 42 Unknown | 0 | 1 | 2 | 0 |
| ASAT, Day 42 Below | 0 | 0 | 0 | 0 |
| ASAT, Day 42 Within | 31 | 29 | 55 | 25 |
| ASAT, Day 42 Above | 0 | 0 | 1 | 1 |
| ASAT, M6 Unknown | 0 | 0 | 1 | 0 |
| ASAT, M6 Below | 0 | 0 | 0 | 0 |
| ASAT, M6 Within | 30 | 28 | 57 | 24 |
| ASAT, M6 Above | 0 | 1 | 0 | 0 |
| Total Bilirubin, Day 0 Unknown | 1 | 1 | 1 | 0 |
| Total Bilirubin, Day 0 Below | 0 | 0 | 0 | 0 |
| Total Bilirubin, Day 0 Within | 29 | 28 | 57 | 0 |
| Total Bilirubin, Day 0 Above | 0 | 2 | 2 | 0 |
| Total Bilirubin, Day 21 Unknown | 1 | 0 | 1 | 0 |
| Total Bilirubin, Day 21 Below | 0 | 0 | 0 | 0 |
| Total Bilirubin, Day 21 Within | 30 | 28 | 55 | 0 |
| Total Bilirubin, Day 21 Above | 0 | 2 | 3 | 0 |
| Total Bilirubin, Day 42 Unknown | 0 | 0 | 2 | 0 |
| Total Bilirubin, Day 42 Below | 0 | 0 | 0 | 0 |
| Total Bilirubin, Day 42 Within | 31 | 30 | 55 | 26 |
| Total Bilirubin, Day 42 Above | 0 | 0 | 1 | 0 |
| Total Bilirubin, M6 Unknown | 0 | 0 | 1 | 0 |
| Total Bilirubin, M6 Below | 0 | 0 | 0 | 0 |
| Total Bilirubin, M6 Within | 30 | 28 | 55 | 24 |
| Total Bilirubin, M6 Above | 0 | 1 | 2 | 0 |
| Bilirubin Conjugated / Direct, Day 0 Unknown | 1 | 1 | 1 | 0 |
| Bilirubin Conjugated / Direct, Day 0 Below | 0 | 0 | 0 | 0 |
| Bilirubin Conjugated / Direct, Day 0 Within | 29 | 30 | 58 | 0 |
| Bilirubin Conjugated / Direct, Day 0 Above | 0 | 0 | 1 | 0 |
| Bilirubin Conjugated / Direct, Day 21 Unknown | 1 | 0 | 1 | 0 |
| Bilirubin Conjugated / Direct, Day 21 Below | 0 | 0 | 0 | 0 |
| Bilirubin Conjugated / Direct, Day 21 Within | 30 | 30 | 58 | 0 |
| Bilirubin Conjugated / Direct, Day 21 Above | 0 | 0 | 0 | 0 |
| Bilirubin Conjugated / Direct, Day 42 Unknown | 0 | 0 | 2 | 0 |
| Bilirubin Conjugated / Direct, Day 42 Below | 0 | 0 | 0 | 0 |
| Bilirubin Conjugated / Direct, Day 42 Within | 31 | 30 | 56 | 26 |
| Bilirubin Conjugated / Direct, Day 42 Above | 0 | 0 | 0 | 0 |

| | | | | |
|---|---|---|---|---|
| Bilirubin Conjugated / Direct, M6 Unknown | 0 | 0 | 1 | 0 |
| Bilirubin Conjugated / Direct, M6 Below | 0 | 0 | 0 | 0 |
| Bilirubin Conjugated / Direct, M6 Within | 30 | 29 | 57 | 24 |
| Bilirubin Conjugated / Direct, M6 Above | 0 | 0 | 0 | 0 |
| Creatine, Day 0 Unknown | 1 | 1 | 1 | 0 |
| Creatine, Day 0 Below | 2 | 0 | 1 | 0 |
| Creatine, Day 0 Within | 27 | 29 | 52 | 0 |
| Creatine, Day 0 Above | 0 | 1 | 6 | 0 |
| Creatine, Day 21 Unknown | 1 | 0 | 1 | 0 |
| Creatine, Day 21 Below | 3 | 0 | 4 | 0 |
| Creatine, Day 21 Within | 27 | 28 | 48 | 0 |
| Creatine, Day 21 Above | 0 | 2 | 6 | 0 |
| Creatine, Day 42 Unknown | 0 | 0 | 2 | 0 |
| Creatine, Day 42 Below | 2 | 1 | 3 | 0 |
| Creatine, Day 42 Within | 28 | 29 | 52 | 24 |
| Creatine, Day 42 Above | 1 | 0 | 1 | 2 |
| Creatine, M6 Unknown | 0 | 0 | 1 | 0 |
| Creatine, M6 Below | 1 | 1 | 2 | 1 |
| Creatine, M6 Within | 28 | 28 | 55 | 22 |
| Creatine, M6 Above | 1 | 0 | 0 | 1 |
| BUN, Day 0 Unknown | 1 | 1 | 1 | 0 |
| BUN, Day 0 Below | 0 | 0 | 2 | 0 |
| BUN, Day 0 Within | 28 | 30 | 57 | 0 |
| BUN, Day 0 Above | 1 | 0 | 0 | 0 |
| BUN, Day 21 Unknown | 1 | 0 | 1 | 0 |
| BUN, Day 21 Below | 1 | 2 | 3 | 0 |
| BUN, Day 21 Within | 29 | 27 | 55 | 0 |
| BUN, Day 21 Above | 0 | 1 | 0 | 0 |
| BUN, Day 42 Unknown | 0 | 0 | 2 | 0 |
| BUN, Day 42 Below | 1 | 2 | 1 | 1 |
| BUN, Day 42 Within | 29 | 28 | 55 | 23 |
| BUN, Day 42 Above | 1 | 0 | 0 | 2 |
| BUN, M6 Unknown | 1 | 0 | 1 | 0 |
| BUN, M6 Below | 1 | 0 | 2 | 0 |
| BUN, M6 Within | 27 | 28 | 54 | 24 |
| BUN, M6 Above | 1 | 1 | 1 | 0 |

Notes:

[31] - The outcome measure for the Flu BS2_3-5 Group was assessed at Day 42 and Month 6 only.

| **End point values** | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 33[32] | 58[33] | | |
| Units: Subjects | | | | |
| ALAT, Day 0 Unknown | 0 | 0 | | |
| ALAT, Day 0 Below | 0 | 0 | | |
| ALAT, Day 0 Within | 0 | 0 | | |
| ALAT, Day 0 Above | 0 | 0 | | |
| ALAT, Day 21 Unknown | 0 | 0 | | |
| ALAT, Day 21 Below | 0 | 0 | | |
| ALAT, Day 21 Within | 0 | 0 | | |

| | | | | |
|---|---|---|---|---|
| ALAT, Day 21 Above | 0 | 0 | | |
| ALAT, Day 42 Unknown | 0 | 0 | | |
| ALAT, Day 42 Below | 0 | 0 | | |
| ALAT, Day 42 Within | 32 | 56 | | |
| ALAT, Day 42 Above | 1 | 1 | | |
| ALAT, M6 Unknown | 0 | 0 | | |
| ALAT, M6 Below | 0 | 0 | | |
| ALAT, M6 Within | 29 | 52 | | |
| ALAT, M6 Above | 0 | 1 | | |
| ASAT, Day 0 Unknown | 0 | 0 | | |
| ASAT, Day 0 Below | 0 | 0 | | |
| ASAT, Day 0 Within | 0 | 0 | | |
| ASAT, Day 0 Above | 0 | 0 | | |
| ASAT, Day 21 Unknown | 0 | 0 | | |
| ASAT, Day 21 Below | 0 | 0 | | |
| ASAT, Day 21 Within | 0 | 0 | | |
| ASAT, Day 21 Above | 0 | 0 | | |
| ASAT, Day 42 Unknown | 0 | 0 | | |
| ASAT, Day 42 Below | 0 | 0 | | |
| ASAT, Day 42 Within | 31 | 55 | | |
| ASAT, Day 42 Above | 2 | 2 | | |
| ASAT, M6 Unknown | 0 | 0 | | |
| ASAT, M6 Below | 0 | 0 | | |
| ASAT, M6 Within | 29 | 50 | | |
| ASAT, M6 Above | 0 | 3 | | |
| Total Bilirubin, Day 0 Unknown | 0 | 0 | | |
| Total Bilirubin, Day 0 Below | 0 | 0 | | |
| Total Bilirubin, Day 0 Within | 0 | 0 | | |
| Total Bilirubin, Day 0 Above | 0 | 0 | | |
| Total Bilirubin, Day 21 Unknown | 0 | 0 | | |
| Total Bilirubin, Day 21 Below | 0 | 0 | | |
| Total Bilirubin, Day 21 Within | 0 | 0 | | |
| Total Bilirubin, Day 21 Above | 0 | 0 | | |
| Total Bilirubin, Day 42 Unknown | 0 | 0 | | |
| Total Bilirubin, Day 42 Below | 0 | 0 | | |
| Total Bilirubin, Day 42 Within | 33 | 55 | | |
| Total Bilirubin, Day 42 Above | 0 | 2 | | |
| Total Bilirubin, M6 Unknown | 0 | 0 | | |
| Total Bilirubin, M6 Below | 0 | 0 | | |
| Total Bilirubin, M6 Within | 29 | 51 | | |
| Total Bilirubin, M6 Above | 0 | 2 | | |
| Bilirubin Conjugated / Direct, Day 0 Unknown | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 0 Below | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 0 Within | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 0 Above | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 21 Unknown | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 21 Below | 0 | 0 | | |

| | | | | |
|---|---|---|---|---|
| Bilirubin Conjugated / Direct, Day 21 Within | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 21 Above | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 42 Unknown | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 42 Below | 0 | 0 | | |
| Bilirubin Conjugated / Direct, Day 42 Within | 33 | 57 | | |
| Bilirubin Conjugated / Direct, Day 42 Above | 0 | 0 | | |
| Bilirubin Conjugated / Direct, M6 Unknown | 0 | 0 | | |
| Bilirubin Conjugated / Direct, M6 Below | 0 | 0 | | |
| Bilirubin Conjugated / Direct, M6 Within | 29 | 53 | | |
| Bilirubin Conjugated / Direct, M6 Above | 0 | 0 | | |
| Creatine, Day 0 Unknown | 0 | 0 | | |
| Creatine, Day 0 Below | 0 | 0 | | |
| Creatine, Day 0 Within | 0 | 0 | | |
| Creatine, Day 0 Above | 0 | 0 | | |
| Creatine, Day 21 Unknown | 0 | 0 | | |
| Creatine, Day 21 Below | 0 | 0 | | |
| Creatine, Day 21 Within | 0 | 0 | | |
| Creatine, Day 21 Above | 0 | 0 | | |
| Creatine, Day 42 Unknown | 0 | 0 | | |
| Creatine, Day 42 Below | 1 | 2 | | |
| Creatine, Day 42 Within | 31 | 51 | | |
| Creatine, Day 42 Above | 1 | 4 | | |
| Creatine, M6 Unknown | 0 | 0 | | |
| Creatine, M6 Below | 0 | 5 | | |
| Creatine, M6 Within | 29 | 47 | | |
| Creatine, M6 Above | 0 | 1 | | |
| BUN, Day 0 Unknown | 0 | 0 | | |
| BUN, Day 0 Below | 0 | 0 | | |
| BUN, Day 0 Within | 0 | 0 | | |
| BUN, Day 0 Above | 0 | 0 | | |
| BUN, Day 21 Unknown | 0 | 0 | | |
| BUN, Day 21 Below | 0 | 0 | | |
| BUN, Day 21 Within | 0 | 0 | | |
| BUN, Day 21 Above | 0 | 0 | | |
| BUN, Day 42 Unknown | 0 | 0 | | |
| BUN, Day 42 Below | 0 | 0 | | |
| BUN, Day 42 Within | 32 | 56 | | |
| BUN, Day 42 Above | 1 | 1 | | |
| BUN, M6 Unknown | 0 | 0 | | |
| BUN, M6 Below | 0 | 0 | | |
| BUN, M6 Within | 27 | 53 | | |
| BUN, M6 Above | 2 | 0 | | |

Notes:

[32] - The outcome measure for the Flu BS2_6-9 Group was assessed at Day 42 and Month 6 only.

[33] - The outcome measure for the Flu BS2_10-17 Group was assessed at Day 42 and Month 6 only.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

SAEs:During the entire study period(Day 0 to Month 6), Solicited local and general symptoms: During the 7-day(Days 0-6) post-vaccination period; Unsolicited symptoms:Within the 84-day or from 63-day follow-up period after the 1st and 2nd dose,respectively

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 13.1 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Flu BS1_3-5 Years Group |

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| | |
|---|---|
| Reporting group title | Flu BS1_6-9 Years Group |

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| | |
|---|---|
| Reporting group title | Flu BS1_10-17 Years Group |

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 0 (before the first vaccination);
On Day 21 (before the second vaccination);
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);

| | |
|---|---|
| Reporting group title | Flu BS2_3-5 Years Group |

Reporting group description:

Subjects 3 to 5 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| | |
|---|---|
| Reporting group title | Flu BS2_6-9 Years Group |

Reporting group description:

Subjects 6 to 9 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| | |
|---|---|
| Reporting group title | Flu BS2_10-17 Years Group |

Reporting group description:

Subjects 10 to 17 years of age, received 2 doses of the GSK2340272A vaccine (Flu) at Day 0 and Day 21 with blood sampling schedule as follows:
On Day 42 (21 days after the second vaccination);
At Month 6 (6 months after the first vaccination);
At Month 12 (one year after the first vaccination).

| **Serious adverse events** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 31 (3.23%) | 1 / 60 (1.67%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Forearm fracture | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 1 / 31 (3.23%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Ectopic pregnancy | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Ranula | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| alternative assessment type: Non-systematic | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 1 / 60 (1.67%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Febrile infection | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Flu BS2_3-5 Years Group | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 34 (0.00%) | 3 / 58 (5.17%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Injury, poisoning and procedural complications | | | |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Forearm fracture | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| Ectopic pregnancy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Ranula | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Febrile infection | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Flu BS1_3-5 Years Group | Flu BS1_6-9 Years Group | Flu BS1_10-17 Years Group |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 30 / 31 (96.77%) | 25 / 31 (80.65%) | 56 / 60 (93.33%) |
| Nervous system disorders | | | |
| Headache (Non-systematic) | | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 9 / 31 (29.03%) | 30 / 60 (50.00%) |
| occurrences (all) | 1 | 14 | 47 |

| | | | |
|---|---|---|---|
| Somnolence | | | |
| subjects affected / exposed | 11 / 31 (35.48%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences (all) | 16 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 15 / 31 (48.39%) | 7 / 31 (22.58%) | 19 / 60 (31.67%) |
| occurrences (all) | 22 | 10 | 22 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 31 (3.23%) | 2 / 60 (3.33%) |
| occurrences (all) | 1 | 1 | 2 |
| Pain | | | |
| subjects affected / exposed | 19 / 31 (61.29%) | 24 / 31 (77.42%) | 51 / 60 (85.00%) |
| occurrences (all) | 29 | 40 | 92 |
| Swelling | | | |
| subjects affected / exposed | 13 / 31 (41.94%) | 13 / 31 (41.94%) | 21 / 60 (35.00%) |
| occurrences (all) | 16 | 18 | 28 |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 7 / 31 (22.58%) | 11 / 60 (18.33%) |
| occurrences (all) | 0 | 10 | 14 |
| Diarrhoea | | | |
| subjects affected / exposed | 6 / 31 (19.35%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences (all) | 7 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 13 / 31 (41.94%) | 29 / 60 (48.33%) |
| occurrences (all) | 0 | 18 | 37 |
| Gastro-intestinal symptoms | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 7 / 31 (22.58%) | 18 / 60 (30.00%) |
| occurrences (all) | 0 | 11 | 21 |
| Headache (Systematic) | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 9 / 31 (29.03%) | 30 / 60 (50.00%) |
| occurrences (all) | 1 | 14 | 47 |
| Irritability | | | |
| subjects affected / exposed | 9 / 31 (29.03%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences (all) | 13 | 0 | 0 |
| Myalgia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 31 (0.00%) | 6 / 31 (19.35%) | 21 / 60 (35.00%) |
| occurrences (all) | 0 | 10 | 26 |
| Chills | | | |
| subjects affected / exposed | 7 / 31 (22.58%) | 7 / 31 (22.58%) | 18 / 60 (30.00%) |
| occurrences (all) | 11 | 8 | 24 |
| Eye disorders | | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 31 (3.23%) | 0 / 60 (0.00%) |
| occurrences (all) | 3 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 5 / 31 (16.13%) | 1 / 31 (3.23%) | 0 / 60 (0.00%) |
| occurrences (all) | 7 | 1 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Eczema | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 14 / 31 (45.16%) | 16 / 31 (51.61%) | 23 / 60 (38.33%) |
| occurrences (all) | 18 | 20 | 34 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 4 / 31 (12.90%) | 9 / 60 (15.00%) |
| occurrences (all) | 4 | 4 | 10 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 2 / 31 (6.45%) | 0 / 60 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Infections and infestations | | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 31 (12.90%) | 1 / 31 (3.23%) | 5 / 60 (8.33%) |
| occurrences (all) | 4 | 2 | 5 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 31 (0.00%) | 3 / 60 (5.00%) |
| occurrences (all) | 3 | 0 | 4 |
| Rhinitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 3 / 31 (9.68%) | 1 / 31 (3.23%) | 2 / 60 (3.33%) |
| occurrences (all) | 3 | 1 | 2 |
| Bronchitis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 31 (0.00%) | 2 / 60 (3.33%) |
| occurrences (all) | 2 | 0 | 2 |
| Gastroenteritis | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 31 (0.00%) | 0 / 60 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Lice infestation | | | |
| subjects affected / exposed | 1 / 31 (3.23%) | 1 / 31 (3.23%) | 0 / 60 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Otitis externa | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 0 / 31 (0.00%) | 1 / 60 (1.67%) |
| occurrences (all) | 2 | 0 | 1 |
| Otitis media | | | |
| subjects affected / exposed | 0 / 31 (0.00%) | 0 / 31 (0.00%) | 1 / 60 (1.67%) |
| occurrences (all) | 0 | 0 | 1 |
| Viral infection | | | |
| subjects affected / exposed | 2 / 31 (6.45%) | 2 / 31 (6.45%) | 1 / 60 (1.67%) |
| occurrences (all) | 2 | 2 | 1 |

| **Non-serious adverse events** | Flu BS2_3-5 Years Group | Flu BS2_6-9 Years Group | Flu BS2_10-17 Years Group |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 26 / 30 (86.67%) | 26 / 34 (76.47%) | 50 / 58 (86.21%) |
| Nervous system disorders | | | |
| Headache (Non-systematic) | | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 10 / 34 (29.41%) | 31 / 58 (53.45%) |
| occurrences (all) | 4 | 13 | 50 |
| Somnolence | | | |
| subjects affected / exposed | 9 / 30 (30.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences (all) | 11 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 15 / 30 (50.00%) | 9 / 34 (26.47%) | 12 / 58 (20.69%) |
| occurrences (all) | 22 | 11 | 14 |

| | | | |
|---|---|---|---|
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 34 (0.00%) | 4 / 58 (6.90%) |
| occurrences (all) | 1 | 0 | 4 |
| Pain | | | |
| subjects affected / exposed | 21 / 30 (70.00%) | 25 / 34 (73.53%) | 45 / 58 (77.59%) |
| occurrences (all) | 38 | 42 | 75 |
| Swelling | | | |
| subjects affected / exposed | 9 / 30 (30.00%) | 9 / 34 (26.47%) | 25 / 58 (43.10%) |
| occurrences (all) | 13 | 13 | 38 |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 7 / 34 (20.59%) | 14 / 58 (24.14%) |
| occurrences (all) | 2 | 9 | 17 |
| Diarrhoea | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 11 / 34 (32.35%) | 24 / 58 (41.38%) |
| occurrences (all) | 0 | 15 | 36 |
| Gastro-intestinal symptoms | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 6 / 34 (17.65%) | 12 / 58 (20.69%) |
| occurrences (all) | 0 | 7 | 13 |
| Headache (Systematic) | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 10 / 34 (29.41%) | 31 / 58 (53.45%) |
| occurrences (all) | 4 | 13 | 50 |
| Irritability | | | |
| subjects affected / exposed | 9 / 30 (30.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences (all) | 14 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 7 / 34 (20.59%) | 24 / 58 (41.38%) |
| occurrences (all) | 1 | 12 | 29 |
| Chills | | | |
| subjects affected / exposed | 3 / 30 (10.00%) | 3 / 34 (8.82%) | 17 / 58 (29.31%) |
| occurrences (all) | 4 | 4 | 22 |
| Eye disorders | | | |
| Conjunctivitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences (all) | 1 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 2 / 34 (5.88%) | 2 / 58 (3.45%) |
| occurrences (all) | 10 | 3 | 3 |
| Skin and subcutaneous tissue disorders | | | |
| Eczema | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 14 / 30 (46.67%) | 12 / 34 (35.29%) | 23 / 58 (39.66%) |
| occurrences (all) | 21 | 16 | 30 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 5 / 30 (16.67%) | 6 / 34 (17.65%) | 9 / 58 (15.52%) |
| occurrences (all) | 6 | 6 | 10 |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 0 / 34 (0.00%) | 2 / 58 (3.45%) |
| occurrences (all) | 5 | 0 | 3 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 2 / 34 (5.88%) | 4 / 58 (6.90%) |
| occurrences (all) | 6 | 2 | 5 |
| Rhinitis | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 34 (2.94%) | 1 / 58 (1.72%) |
| occurrences (all) | 2 | 1 | 1 |
| Bronchitis | | | |
| subjects affected / exposed | 4 / 30 (13.33%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences (all) | 5 | 0 | 1 |
| Gastroenteritis | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences (all) | 2 | 0 | 1 |

| | | | |
|---|---|---|---|
| Lice infestation | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 1 / 34 (2.94%) | 1 / 58 (1.72%) |
| occurrences (all) | 2 | 1 | 1 |
| Otitis externa | | | |
| subjects affected / exposed | 0 / 30 (0.00%) | 0 / 34 (0.00%) | 1 / 58 (1.72%) |
| occurrences (all) | 0 | 0 | 1 |
| Otitis media | | | |
| subjects affected / exposed | 2 / 30 (6.67%) | 0 / 34 (0.00%) | 0 / 58 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Viral infection | | | |
| subjects affected / exposed | 1 / 30 (3.33%) | 0 / 34 (0.00%) | 3 / 58 (5.17%) |
| occurrences (all) | 1 | 0 | 3 |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 30 August 2010 | Following the very high immune response after the first two doses of vaccine, in addition to the decreased perception of the pandemic threat by the public and in the light of a potential increase of overall reactogenicity, the added value of the booster dose was considered limited by the investigators. Thus no subject enrolled in Flu D-Pan H1N1-023 study were vaccinated with the booster dose. The safety follow-up was thus reduced to Month 12, i.e. 12 months after the first vaccination, instead of 12 months after the booster dose. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported